Related Experiment Video
Updated: Jun 14, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Optimizing drug-resistant epilepsy identification in the Veterans Health Administration
Zulfi Haneef1, Stephan Eisenschenk2, Maria R Lopez3
1Epilepsy Centers of Excellence. Veterans Administration Central Office, Washington, DC, United States; Michael E. DeBakey VA Medical Center, Houston, TX 77030, United States; Baylor College of Medicine, Houston, TX 77030, United States.
Background:
Accurate identification of drug-resistant epilepsy (DRE) is crucial for accurate disease measurement, effective clinical intervention and improved patient outcomes. Prior attempts to define DRE in administrative data using the 2010 International League against Epilepsy (ILAE) criteria have faced complexities.
Methods:
This retrospective study utilized national administrative data from the Veterans Health Administration (VHA) to identify patients with possible DRE. This was a multicenter national cohort that uses a common, non-commercial medical record system. A panel of six epileptologists conducted chart reviews to identify DRE using the 2010 ILAE criteria. Logistic regression was used to analyze epilepsy-related variables of interest to develop algorithms identifying DRE.
Results:
Among 260 included patients, 93 (35.8 %) had DRE, 148 (56.9 %) did not have DRE, and 19 (7.3 %) were undetermined. Out of 96 algorithms assessed, the best-performing algorithm had a high accuracy (F1 score=0.726) and defined DRE as those on ≥ 3 ASMs in addition to those on ≥ 2 ASMs for ≥ 365 days with at least one intractable ICD code. The algorithm demonstrated high sensitivity (0.74), specificity (0.81), and area under the curve (AUC 0.78). Factors such as age, number of ASMs, EEG, and MRI procedures, and intractable epilepsy ICD codes were associated with DRE.
Discussion:
Our optimal algorithm for DRE identification is like previously published algorithms that determined the importance of number and duration of ASMs. However, it differs in the particular combination of factors that best identified DRE. These differences highlight the importance of fine-tuning algorithms for specific care settings. Further validation in a larger, more heterogenous cohort are needed to determine our algorithm's applicability and potential impact.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Glutamate Antagonists

